Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.

Sebestyén A, Sticz TB, Márk A, Hajdu M, Timár B, Nemes K, Nagy N, Váradi Z, Kopper L.

Mod Pathol. 2012 Dec;25(12):1623-8. doi: 10.1038/modpathol.2012.141. Epub 2012 Aug 17.

2.

Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Li SH, Huang EY, Lu HI, Huang WT, Yen CC, Huang WC, Chen CH.

J Thorac Cardiovasc Surg. 2012 Dec;144(6):1352-9, 1359.e1. doi: 10.1016/j.jtcvs.2012.06.049. Epub 2012 Jul 25.

3.

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

Villarreal-Garza C, Cortes J, Andre F, Verma S.

Ann Oncol. 2012 Oct;23(10):2526-35. Epub 2012 May 2. Review.

PMID:
22553196
4.

mTOR signaling in growth control and disease.

Laplante M, Sabatini DM.

Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. Review.

5.

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.

Currin ES, Gopal AK.

Korean J Hematol. 2012 Mar;47(1):8-16. doi: 10.5045/kjh.2012.47.1.8. Epub 2012 Mar 28.

6.

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP.

Ann Oncol. 2012 Oct;23(10):2663-70. Epub 2012 Apr 3.

PMID:
22473592
7.

Targeting PI3 kinase/AKT/mTOR signaling in cancer.

Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA.

Crit Rev Oncog. 2012;17(1):69-95. Review.

PMID:
22471665
8.

Everolimus: targeted therapy on the horizon for the treatment of breast cancer.

Barnett CM.

Pharmacotherapy. 2012 Apr;32(4):383-96. doi: 10.1002/j.1875-9114.2012.01084.x. Review.

PMID:
22461124
9.

The mTOR signalling pathway in human cancer.

Pópulo H, Lopes JM, Soares P.

Int J Mol Sci. 2012;13(2):1886-918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10. Review.

10.

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.

Khokhar NZ, Altman JK, Platanias LC.

Curr Opin Oncol. 2011 Nov;23(6):578-86. doi: 10.1097/CCO.0b013e32834b892d. Review.

PMID:
21892085
11.

Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

Schatz JH.

Curr Oncol Rep. 2011 Oct;13(5):398-406. doi: 10.1007/s11912-011-0187-7.

PMID:
21755275
12.

mTOR complex 2 signaling and functions.

Oh WJ, Jacinto E.

Cell Cycle. 2011 Jul 15;10(14):2305-16. Epub 2011 Jul 15. Review.

13.

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC.

Target Oncol. 2011 Jun;6(2):69-94. doi: 10.1007/s11523-011-0178-5. Epub 2011 May 4. Review.

PMID:
21541789
14.

Mammalian target of rapamycin as a target in hematological malignancies.

Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS.

Target Oncol. 2011 Mar;6(1):53-61. doi: 10.1007/s11523-011-0175-8. Epub 2011 Apr 17. Review.

PMID:
21499765
15.

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.

Steidl C, Connors JM, Gascoyne RD.

J Clin Oncol. 2011 May 10;29(14):1812-26. doi: 10.1200/JCO.2010.32.8401. Epub 2011 Apr 11. Review.

PMID:
21483001
16.

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.

Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M, Luminari S, Ferretti S, Johannesen TB, Sankila R, Karjalainen-Lindsberg ML, Simonetti A, Martos MC, Raphaël M, Giraldo P, Sant M; HAEMACARE Working Group.

Haematologica. 2011 May;96(5):720-8. doi: 10.3324/haematol.2010.034264. Epub 2011 Feb 17.

17.

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Jona A, Younes A.

Blood Rev. 2010 Nov;24(6):233-8. doi: 10.1016/j.blre.2010.08.003. Epub 2010 Sep 15. Review.

18.

Target of rapamycin signaling in leukemia and lymphoma.

Vu C, Fruman DA.

Clin Cancer Res. 2010 Nov 15;16(22):5374-80. doi: 10.1158/1078-0432.CCR-10-0480. Epub 2010 Sep 8. Review.

19.

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.

Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D.

Leukemia. 2010 Oct;24(10):1686-99. doi: 10.1038/leu.2010.170. Epub 2010 Aug 12. Review.

PMID:
20703258
20.

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

Ferté C, André F, Soria JC.

Nat Rev Clin Oncol. 2010 Jul;7(7):367-80. doi: 10.1038/nrclinonc.2010.84. Epub 2010 Jun 15. Review.

PMID:
20551944

Supplemental Content

Support Center